Inhibikase Therapeutics (NASDAQ:IKT – Get Free Report) and Biofrontera (NASDAQ:BFRI – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, profitability, risk, earnings, analyst recommendations and valuation.
Valuation & Earnings
This table compares Inhibikase Therapeutics and Biofrontera”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Inhibikase Therapeutics | $260,000.00 | 1,239.76 | -$48.26 million | ($0.43) | -5.37 |
| Biofrontera | $41.71 million | 0.43 | -$10.54 million | ($0.45) | -2.69 |
Volatility and Risk
Inhibikase Therapeutics has a beta of 0.95, suggesting that its share price is 5% less volatile than the S&P 500. Comparatively, Biofrontera has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of current recommendations and price targets for Inhibikase Therapeutics and Biofrontera, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Inhibikase Therapeutics | 1 | 1 | 4 | 3 | 3.00 |
| Biofrontera | 1 | 1 | 1 | 0 | 2.00 |
Inhibikase Therapeutics presently has a consensus price target of $5.40, suggesting a potential upside of 133.77%. Given Inhibikase Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Inhibikase Therapeutics is more favorable than Biofrontera.
Profitability
This table compares Inhibikase Therapeutics and Biofrontera’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Inhibikase Therapeutics | N/A | -42.80% | -40.58% |
| Biofrontera | -13.78% | -145.81% | -31.30% |
Insider & Institutional Ownership
3.8% of Inhibikase Therapeutics shares are held by institutional investors. Comparatively, 10.1% of Biofrontera shares are held by institutional investors. 7.1% of Inhibikase Therapeutics shares are held by insiders. Comparatively, 8.1% of Biofrontera shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Summary
Inhibikase Therapeutics beats Biofrontera on 9 of the 15 factors compared between the two stocks.
About Inhibikase Therapeutics
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson’s Disease (PD) and related disorders that arise inside and outside of the brain. The company’s product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.
About Biofrontera
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
Receive News & Ratings for Inhibikase Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inhibikase Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
